In Early Lung Cancer, Immunotherapy Plus Targeted Radiation May Up Response Rate In Early Lung Cancer, Immunotherapy Plus Targeted Radiation May Up Response Rate
Patients with non-small-cell lung cancer may respond more quickly to neoadjuvant durvalumab combined with stereotactic body radiotherapy than to immunotherapy alone, an early industry-funded trial suggests.Reuters Health Information
Source: Medscape Radiology Headlines - Category: Radiology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Immunotherapy | Lung Cancer | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Radiology